The latest announcement is out from Purple Biotech ( (PPBT) ).
Purple Biotech announced its participation in the Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025, where CEO Gil Efron will join a panel discussion on new radiotherapy and targeted therapy approaches. This engagement highlights Purple Biotech’s active role in the oncology field and its commitment to advancing its therapeutic pipeline, potentially impacting its market positioning and stakeholder interests.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company based in Rehovot, Israel, focused on developing first-in-class therapies to address tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications through innovative mechanisms such as monoclonal antibodies and tri-specific antibodies.
YTD Price Performance: -42.05%
Average Trading Volume: 27,757
Technical Sentiment Signal: Buy
Current Market Cap: $7.4M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.